Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. - Wikidata - awgldk - TriplyDB

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

http://www.wikidata.org/entity/Q37324241

about

Patient-derived tumour xenografts as models for oncology drug development Patient-derived tumor xenografts: transforming clinical samples into mouse models Rebuilding cancer metastasis in the mouse Current status and evolution of preclinical drug development models of epithelial ovarian cancer Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer The future of patient-derived tumor xenografts in cancer treatment.Ex vivo tumor culture systems for functional drug testing and therapy response prediction Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis Guidelines for the welfare and use of animals in cancer research.Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice Establishment of genetically diverse patient-derived xenografts of colorectal cancer.Pre-clinical mouse models of human prostate cancer and their utility in drug discovery Prediction of individual response to anticancer therapy: historical and future perspectives Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing New concepts in breast cancer genomics and genetics Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.Normal tissue protection for improving radiotherapy: Where are the Gaps?Genomic profiling of patient-derived colon cancer xenograft models Preclinical models of pancreatic ductal adenocarcinoma.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.HER2 as a novel therapeutic target for cervical cancer.Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer.Origin of the vasculature supporting growth of primary patient tumor xenografts.Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.Xenograft models of head and neck cancers.Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.Human tumor xenografts and mouse models of human tumors: re-discovering the models.Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Modeling of Patient-Derived Xenografts in Colorectal Cancer.

P2860

Q24604068-6908BA57-AD96-4D96-950C-AED63F442A93 Q24627425-CE231ED9-62B2-40E6-8B53-1CD6F4A40731 Q26864450-DE24AB11-CD4F-4E4B-B932-FA3AE44D10F6 Q27028117-C1394A41-5C7B-4072-9427-0EF2E1F7D537 Q28534618-B752774D-95F1-4138-8686-BB31FCB254C1 Q28552408-F64249D1-39F6-4629-885E-1C46D11F75F2 Q30409503-60728BCB-C375-410C-A80F-16DF6CA9C8E3 Q33361578-F9E4BD5F-FB06-4A0D-B1A7-784602B62883 Q33827247-474B637E-9743-49CA-9C0D-BEF36AA8890D Q33827461-8365C1CF-14A4-4463-B516-C07D7F1B486C Q33903753-21E3A505-B4A9-4A0C-8017-71CA7F864E10 Q34122822-964F8282-E97A-4E6A-A144-FBA5047728E5 Q34258171-C44A62FB-C5CC-4294-BF5E-7881C4253257 Q34309954-E87C05D5-4289-4AB0-81AD-07E5C7E91FAF Q34372342-F2F58DF6-800C-48B2-8B30-ADBD1CF52BC1 Q34704942-5BAE99AD-B1CC-44FB-ACA7-6C2F9C2A65A4 Q34771567-60A4E7E6-6BA2-4231-B41A-3B60AF5CD386 Q35024682-B9167679-84F2-4BD1-B356-7CB22F636AB4 Q35041892-F95F9701-240D-462B-B425-2A87A876CF77 Q35258057-61DEAA62-38EC-450C-A679-76412DF52905 Q35534811-103271CF-10F9-4BEB-8626-FB5A37759EB2 Q35638497-53B41798-92B3-47D0-AE7A-7E9A16C2BA1C Q35839058-260FCD06-E348-4DF9-B28D-41F8B6DA161C Q35878951-C6BEE0B0-2E06-4144-B431-05CE7523835E Q36137870-FCE655E3-4F21-4F03-9987-9578FDF3BB2E Q36153954-A2AE796A-FD91-4BC0-8956-AB471FA9F9AC Q36428208-83E6E834-D5BA-4C33-8033-E2F6F8D3B39F Q36521908-E6AF0EE9-CA31-433E-A51C-2B7D0338EBF6 Q36546614-7320634D-8580-41D1-98D7-F6CBFF103247 Q36633405-E1D8F7D1-3015-4793-9ADA-58D96622D1FF Q36863454-E6FA86E8-8B53-4B06-8B26-AD649DB7C9E3 Q37086209-B8062F9F-1FC7-434B-9588-2030182D7697 Q37272622-36DB88D4-3581-4EAB-AA16-5A03FDA1821D Q37332682-6B923703-7273-4482-ABF0-962BAD437972 Q37542817-7F737EDB-73F2-4B65-935C-79CA67971EA7 Q38045441-ED9B60C4-669E-4392-B9D3-1391C0C843F1 Q38088348-7F7DB856-DC03-4714-9532-CBED40EAC198 Q38233004-12257B83-C7FA-4578-B62D-547B185F0252 Q38351470-4BB635F9-8EBA-40B8-952B-AAD111870412 Q38705019-1BBE451C-D60A-4CA1-A20A-E6C7E6202EDC

P2860

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

http://www.wikidata.org/entity/Q37324241

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Direct in vivo xenograft tumor ...... g response in cancer patients.

@en

Direct in vivo xenograft tumor ...... g response in cancer patients.

@nl

type

label

Direct in vivo xenograft tumor ...... g response in cancer patients.

@en

Direct in vivo xenograft tumor ...... g response in cancer patients.

@nl

prefLabel

Direct in vivo xenograft tumor ...... g response in cancer patients.

@en

Direct in vivo xenograft tumor ...... g response in cancer patients.

@nl

P1433

Q37324241-FC4DC900-4348-4FFF-B1AC-078D064A638F

P1476

Q37324241-F6B8B558-7265-4CF9-A7CD-8BCB009EB1CE

P2093

Q37324241-110FE481-4143-4D8B-9A04-D1D0029E5EAB

Q37324241-23030E6F-6353-4B51-AEFF-E26E266D98CE

P2860

Q37324241-04A33FDB-C606-49AC-8409-78422EDB2E40

Q37324241-137029BE-7463-4623-9FA4-D5342EA44CA9

Q37324241-17C5B008-1E9A-4868-AC78-9DB68E4B42C5

Q37324241-35EB3A2A-C033-4697-A378-B5CEC0646326

Q37324241-3B4822A8-E8C1-4F00-821D-BB465EE3D59E

Q37324241-46F9B080-4BBE-4A22-BFEA-26FEA66ECD8A

Q37324241-7165FA1A-1320-4B42-A1DD-2347D6861716

Q37324241-83B0B27B-687F-4A7C-AD94-68CC1AB5FF07

Q37324241-86BDDD0D-5EB9-4DEC-8D5E-AA47E90E266F

Q37324241-AAD2EF9A-714B-4C43-8690-3BEEFB8E3FDB

P2888

Q37324241-2BEE7341-3CA1-49DA-91F5-6D8B2765AFFD

P304

Q37324241-C9821D93-B5A5-44D2-A742-DFA28A0A38B5

P31

Q37324241-9D5561BB-477E-46F7-B61A-DE2B616C79F5

P356

Q37324241-117763ED-D4D4-4700-8E3B-5830C5DFB56A

P407

Q37324241-83AF2712-EA66-4519-91D7-59047265A160

P433

Q37324241-1832C083-D02B-4C30-99FD-E53AAB0B9CBC

P478

Q37324241-8223A764-19E4-4595-9362-9F4DFFFD535B

P577

Q37324241-ED42EB4E-3A64-45FA-869A-9BA9C56522C9

P6179

Q37324241-84798F3A-4C58-4FB7-B905-E4DBC55C7591

P698

Q37324241-A1A6814F-2A30-477A-B2FA-84254A6BAF80

P921

Q37324241-452C98EF-7631-4969-B53F-0C640D359F86

Q37324241-9C3FC6FA-176C-48B0-BCAC-A67FEC4CE9AF

Q37324241-D0C1D022-5548-4FCD-BE19-5A841174585A

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Direct in vivo xenograft tumor ...... g response in cancer patients.

@en

P2093

B Rubio-Viqueira

http://www.w3.org/2001/XMLSchema#string

M Hidalgo

http://www.w3.org/2001/XMLSchema#string

P2860

The price of innovation: new estimates of drug development costs

Phenotypic instability of Saos-2 cells in long-term culture

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.

Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies.

Scaling down imaging: molecular mapping of cancer in mice.

Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.

Role of tissue stroma in cancer cell invasion.

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.

Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

P2888

P304

217-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2008.200

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021014583

http://www.w3.org/2001/XMLSchema#string

P698

19005462

http://www.w3.org/2001/XMLSchema#string

P921